Biotechnology

Protagonist Therap

Protagonist Therapeutics released FY2026 Q1 earnings on May 5, 2026 (EST), actual revenue USD 56.37 M (forecast USD 16.27 M), actual EPS USD 0.05 (forecast USD -0.6033)

Protagonist Exercised U.S. Option to Terminate Rusfertide Collaboration with Takeda

Protagonist Therapeutics' Chief Medical Officer Arturo Molina Sells 15,000 Shares

Harold E. Selick Exercises Stock Options and Sells Shares

Protagonist Therapeutics CFO Ali Asif sells stocks

Protagonist Therapeutics CEO sells company stocks

Protagonist Therap released FY2025 earnings on February 25 (EST), actual revenue USD 46.02 M (forecast USD 50.48 M), actual EPS USD -2.0499 (forecast USD -1.8788)

Protagonist Therap released FY2025 Q4 earnings on February 25 (EST), actual revenue USD 7.437 M (forecast USD 14.92 M), actual EPS USD -0.6982 (forecast USD -0.495)

Protagonist Therapeutics Quarterly Earnings Missed Expectations

Takeda and Protagonist Announce 52-Week Data for Rusfertide and Plan to Seek Regulatory Approval

Protagonist Therapeutics Sees Significant Revenue Growth with Janssen Collaboration

H.C. Wainwright Analyst Reiterates Buy Rating on Protagonist Therapeutics

Protagonist Therapeutics Reports Lower-than-Expected Quarterly Earnings, Stock Price Drops

H.C. Wainwright Maintains Buy Rating on Protagonist Therapeutics

Protagonist Therap released FY2025 9 Months Earnings on November 6, 2025 (EST), with actual revenue of USD 38.58 M and EPS of USD -1.3599

Protagonist Therap released FY2025 Q3 earnings on November 6 (EST), actual revenue USD 4.712 M (forecast USD 4.136 M), actual EPS USD -0.62 (forecast USD -0.6375)

Tara Bancroft gives Protagonist Therapeutics a Buy Rating

Protagonist Therapeutics to Present New Clinical Data for Rusfertide at ASH Annual Meeting

Wedbush 下调 Protagonist Therapeutics 2029 财年收益预期至每股 2.27 美元

Protagonist Therapeutics Receives Upgrade to $86 Target Price from Yun Zhong

Netcapital

Agape ATP

Tradr 2X Long QBTS Daily ETF

Akanda

Defiance Daily Target 2X Long RGTI ETF

PicoCELA

Tradr 2X Long RGTI Daily ETF

Co-Diagnostics

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NewGenIvf

PTGX

ACOG

ARKG

SBIO

LABU

Genvor, Inc. has appointed Donald Kalkofen as Chief Financial Officer to lead its financial strategy as the company pursues growth in agriculture and human health markets. Kalkofen brings over 20 years of experience in public company finance, including successful IPOs. He previously served as CFO at Alpha Cognition and Protagonist Therapeutics, guiding them through significant growth and public listings. Genvor aims to leverage his expertise to strengthen its financial foundation and advance its dual-market commercialization plans.

StockTitan

Alpha Cognition

Health Care Select Sector SPDR

VanEck Biotech ETF

SPDR S&P Biotech

iShares Global Healthcare

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

VG Health

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

iShares US Pharma

Genvor Appoints Donald Kalkofen as Chief Financial Officer | GNVR Stock News

Dinesh V. Patel, President and CEO of Protagonist Therapeutics, sold shares worth $7.5 million at an average price of $100.12 per share. Following the sale, he retains ownership of 523,478 shares. The sale involved multiple transactions with prices ranging from $98.83 to $103.50, as reported in SEC Form 4 filings.

TradingView

Protagonist Therapeutics President, CEO Sold Shares Worth Over $7.5M

H.C. Wainwright analyst Douglas Tsao has reaffirmed a Buy rating for Protagonist Therapeutics (PTGX) with a price target of $117.00. Tsao, who specializes in the Healthcare sector, has an average return of 21.2% and a 52.10% success rate on his stock recommendations. Additionally, Barclays analyst Etzer Darout also issued a Buy rating for the company, while Goldman Sachs maintained a Hold rating on the stock.

Tip Ranks

Pacira BioSciences

Rezolute

Xenon Pharma

Barclays

Goldman Sachs

GS Hldg R

H.C. Wainwright Sticks to Their Buy Rating for Protagonist Therapeutics (PTGX)

Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration | PTGX Stock News

Takeda Pharmaceutical Company

Takeda Pharmaceutical Co. Ltd.

Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration | PTGX Stock News

DUOT

The US market has seen a 1.7% increase over the past week and a 34% rise over the last year, with earnings expected to grow by 16% annually. Key high-growth tech stocks include Duos Technologies Group, Fabrinet, and Clear Secure, showcasing strong revenue and earnings growth. Duos Technologies focuses on intelligent tech solutions, Fabrinet excels in optical manufacturing, and Clear Secure specializes in biometric identity verification. Each company demonstrates significant innovation and strategic investments, positioning them well for future growth in a thriving market.

Protagonist Therap(PTGX.US)

Genvor Appoints Donald Kalkofen as Chief Financial Officer | GNVR Stock News

Protagonist Therapeutics President, CEO Sold Shares Worth Over $7.5M

H.C. Wainwright Sticks to Their Buy Rating for Protagonist Therapeutics (PTGX)

Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration | PTGX Stock News

US High Growth Tech Stocks To Watch In April 2026